郭敬志;刘旭辉;刘庆乐;

• 1:河南中医药大学第三附属医院
• 2:郑州市第六人民医院

摘要(Abstract)：

目的探讨Brunnstrom技术联合依达拉奉对脑卒中患者的治疗效果及肢体功能康复的影响。方法纳入2017-08—2019-08河南中医药大学三附院接诊的80例脑卒中患者,观察组与对照组各40例。所有患者给予常规治疗,对照组加用依达拉奉治疗,观察组在对照组基础上联合Brunnstrom技术干预,对比2组患者的临床疗效、认知功能、血清学指标、肢体活动功能、不良反应发生率。结果观察组总有效率90.00%(36/40),高于对照组的72.50%(29/40),差异有统计学意义(P<0.05)。治疗后观察组患者的简易智力状态检查量表(MMSE)、蒙特利尔认知评估量表(MoCA)、日常生活活动能力量表(ADL)评分均高于对照组(P<0.05)。治疗后观察组患者的神经元特异性烯醇化酶(NSE)、基质金属蛋白酶-9(MMP-9)、血清同型半胱氨酸(Hcy)水平均低于对照组(P<0.05)。治疗后观察组患者的简式Fugl-Meyer运动功能评分量表上肢运动功能、下肢运动功能、平衡功能、关节活动度评分均高于对照组(P<0.05)。治疗期间患者不良反应发生率对比无显著差异(P>0.05)。结论 Brunnstrom技术联合依达拉奉对脑卒中患者的治疗效果良好,能够提高临床疗效,改善患者的认知功能和血清学指标,提高肢体康复功能,安全性良好。

关键词(KeyWords)： 脑卒中;依达拉奉;Brunnstrom技术;认知功能;肢体运动功能

Abstract:

Keywords:

基金项目(Foundation): 河南省医学科技攻关项目（编号：201702309）

作者(Authors): 郭敬志;刘旭辉;刘庆乐;

参考文献(References)：

• [1]吴连爽，唐茜，王本玄，等.缺血性脑卒中静脉溶栓出血转化风险预测的研究进展[J].中国实用神经疾病杂志，2020,23(19):1744-1748. DOI:10.12083/SYSJ.2020. 16.009.
• [2] WALKER M F,HOFFMANN T C,BRADY M C,et al. Improving the Development,Monitoring and Reporting of Stroke Rehabilitation Research:Consensus-BasedCore Recommendations from the Stroke Recovery and Rehabilitation Roundtable[J]. Neurorehabil Neural Repair,2017,31(11):877-884. DOI:10.1177/1545968317732686.
• [3]渠泽平，吴丽娥.大面积脑梗死诊治研究进展[J].中国实用神经疾病杂志，2018,21(1):114-116. DOI:10.12083/SYSJ.2018.01.030.
• [4] TAI G,CORBEN L A,YIU E M,et al. Progress in the treatment of Friedreich ataxia[J]. Neurol Neurochir Pol,2018,52(2):280-285. DOI:10.1016/j.pjnns.2018.02. 003.
• [5] SHEN L H,CHEN J,SHEN H C,et al.Possible Mechanism of Therapeutic Effect of3-Methyl-1-phenyl-2-pyrazolin-5-oneand Bone Marrow Stromal Cells Combination Treatment in Rat Ischemic Stroke Model[J].Chin Med J(Engl),2016,129(12):1471-1476.DOI:10.4103/0366-6999.183418.
• [6]陈盼，张鑫磊，刘震乾，等.丁苯酞联合依达拉奉治疗急性缺血性脑卒中对细胞凋亡的影响[J].中国实用神经疾病杂志，2019,22(15):1643-1648. DOI:10.12083/SYSJ.2019.15.238.
• [7]刘方，王钊锐，刘恒方，等.老年人-照顾者-护士互动模式对居家脑卒中患者康复效果的影响[J].中国实用神经疾病杂志，2021,24(2):178-184. DOI:10.12083/SYSJ.2021.13.010.
• [8] XU J,WANG Y,WANG A,et al. Safety and efficacy of Edaravone Dexborneol versus edaravone for patients with acute ischaemic stroke:a phase II,multicentre,randomised,double-blind,multiple-dose,active-controlled clinical trial[J]. Stroke Vasc Neurol,2019,4(3):109-114. DOI:10.1136/svn-2018-000221.
• [9] BAO Q,HU P,XU Y,et al.Simultaneous Blood-Brain Barrier Crossing and Protection for Stroke Treatment Based on Edaravone-Loaded Ceria Nanoparticles[J].ACS Nano,2018,12(7):6794-6805. DOI:10.1021/acsnano.8b01994.
• [10] MATSUMOTO S,MUROZONO M,KANAZAWA M,et al. Edaravone and cyclosporine A as neuroprotective agents for acute ischemic stroke[J]. Acute Med Surg,2018,5(3):213-221.DOI:10.1002/ams2.343.
• [11] ASATUROVA A V,EZHOVA L S,FAIZULLINA N M,et al. Expansion of secretory cells in the fallopian tubal epithelium in the early stages of the pathogenesis of ovarian serous carcinomas[J]. Arkh patol,2017,79(3):10-15.DOI:10.17116/patol201779310-18.
• [12] TANAKA M,SUGIMURA N,FUJISAWA A,et al. Stabilizers of edaravone aqueous solution and their action mechanisms. 1.Sodium bisulfite[J]. J Clin Biochem Nutr,2017,61(3):2802-2807. DOI:10.3164/jcbn.17-61.
• [13] WATANABE K,TANAKA M,YUKI S,et al.How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis?[J]. J Clin Biochem Nutr,2018,62(1):20-38. DOI:10.3164/jcbn.17-62.
• [14] BAILLY C,HECQUET P E,KOUACH M,et al. Chemical reactivity and uses of1-phenyl-3-methyl-5-pyrazolone(PMP),also known as edaravone[J]. Bioorg Med Chem,2020,28(10):115463. DOI:10.1016/j.bmc.2020.115463.
• [15] QIAN Y,LYU Y,JIANG M,et al.Human urinary kallidinogenase or edaravone combined with butylphthalide in the treatment of acute ischemic stroke[J]. Brain Behav,2019,9(12):e01438. DOI:10.1002/brb3.1438.
• [16] ZHU F,GAO J,GAO R,et al. Clinical efficacy of electroacupuncture combined with motor imagery therapy on hemiplegic cerebral infarction[J]. Zhongguo Zhen Jiu,2017,37(9):927-931. DOI:10.13703/j.0255-2930.2017.09.004.
• [17] NAGANUMA M,INATOMI Y,NAKAJIMA M,et al. Associations between Uric Acid Level and3-Month Functional Outcome in Acute Ischemic Stroke Patients Treated with/without Edaravone[J]. Cerebrovasc Dis,2018,45(3/4):115-123. DOI:10.1159/000488038.
• [18] TANAHASHI N,YAMAGUCHI T,AWANO H,et al. Outcome of Acute Ischemic Stroke after the Treatment with Edaravone and 0.6 Mg/Kg Alteplase in Japanese Patients with Diabetes[J]. J Stroke Cerebrovasc Dis,2018,27(5):1302-1310. DOI:10.1016/j.jstrokecerebrovasdis.2017.12.019.
• [19] YAMAGUCHI T,AWANO H,MATSUDA H,et al. Edaravone with and without.6Mg/Kg Alteplase within 4.5 Hours after Ischemic Stroke:A Prospective Cohort Study(PROTECT4.5)[J]. J Stroke Cerebrovasc Dis,2017,26(4):756-765. DOI:10.1016/j.jstrokecerebrovasdis.2016.10.011.
• [20] WU H Y,TANG Y,GAO L Y,et al. The synergetic effect of edaravone and borneol in the rat model of ischemic stroke[J]. Eur J Pharmacol,2014,740:522-531. DOI:10.1016/j.ejphar.2014.06.035.
• [21] TANAHASHI N,YAMAGUCHI T,AWANO H,et al. Outcome of Acute Ischemic Stroke after the Treatment with Edaravone and 0.6Mg/Kg Alteplase in Japanese Patients with Diabetes[J]. J Stroke Cerebrovasc Dis,2018,27(5):209-213. DOI:10.1016/j.jstrokecerebrovasdis.2017.12.019.
• [22] PLOW E B,MACHADO A. Invasive neurostimulation in stroke rehabilitation[J].Neurotherapeutics,2014,11(3):572-582.DOI:10.1007/s13311-013-0245-y.
• [23] WU S,SENA E,EGAN K,et al. Edaravone improves functional and structural outcomes in animal models of focal cerebral ischemia:a systematic review[J]. Int J Stroke,2014,9(1):101-106. DOI:10.1111/ijs.12163.
• [24] KAMOUCHI M,SAKAI H,KIYOHARA Y,et al. Acute kidney injury and edaravone in acute ischemic stroke:the Fukuoka Stroke Registry[J]. J Stroke Cerebrovasc Dis,2013,22(8):e470-e476. DOI:10.1016/j.jstrokecerebrovasdis.2013.05.018.
• [25] CHEN X,SUN Z,WANG J,et al. Predicting the Pharmacokinetic Characteristics of Edaravone Intravenous Injection and Sublingual Tablet Through Modeling and Simulation[J]. Clin Ther,2020,42(3):428-438. DOI:10.1016/j.clinthera.2020.01.006.
• [26] ZHENG J, CHEN X. Edaravone offers neuroprotection for acute diabetic stroke patients[J]. Ir J Med Sci,2016,185(4):819-824. DOI:10.1007/s11845-015-1371-9.
• [27] KIM J K,HAU Y S,KWAK S,et al. Essential Medical Information for Stroke Patients Undergoing Interhospital Transfer:A Delphi Study[J]. Am J Phys Med Rehabil,2020,29(12):281-287. DOI:10.1097/PHM.0000000000001573.
• [28] SAITA K,MORISHITA T,HYAKUTAKE K,et al. Feasibility of Robot-assisted Rehabilitation in Poststroke Recovery of Upper Limb Function Depending on the Severity[J].Neurol Med Chir,2020,60(4):281-285. DOI:10.2176/nmc.oa.2019-0268.
• [29] LEE A Y,CHOI K T,CHANG M C.Prediction of Muscle Loss after Stroke by Analysis of Corticospinal Tract[J]. Transl Neurosci,2020,11(1):280-285. DOI:10.1515/tnsci-2020-0114.
• [30] WU D,MA J,ZHANG L,et al. Effect and Safety of Transcutaneous Auricular Vagus Nerve Stimulation on Recovery of Upper Limb Motor Function in Subacute Ischemic Stroke Patients:A Randomized Pilot Study[J].Neural Plast,2020,20(10):1-9. DOI:10.1155/2020/8841752.
• [31] FENG L,LIANG N,LI T,et al. Efficacy and safety of edaravone for acute intracerebral haemorrhage:protocol for a systematic review and meta-analysis[J]. BMJ Open,2020,10(8):e039366. DOI:10.1136/bmjopen-2020-039366.
• [32] LI X,MA D,SUN G. Effects of Edaravone on Neurological Function and Tumor Necrosis Factor Alpha and Interleukin 8 Levels in Patients with Cerebral Infarction[J]. Eur Neurol,2020,83(1):73-79. DOI:10.1159/000505776.
• [33] TANAKA M,SUGIMURA N,FUJISAWA A,et al. Stabilizers of edaravone aqueous solution and their action mechanisms. 1. Sodium bisulfite[J]. J Clin Biochem Nutr,2017,61(3):159-163. DOI:10.3164/jcbn.17-61.
• [34] ZHANG X, YE G, WU Z, et al. The therapeutic effects of edaravone on collagen-nduced arthritis in rats[J]. J Cell Biochem,2019,121(5):289-295. DOI:10.1002/jcb.29382.
• [35] KOCYIGIT B F,AKALTUN M S. Assessment of responsiveness of four hand-related scales in stroke patients[J]. Acta Neurol Belg,2020,28(3):287-294. DOI:10.1007/s13760-020-01443-x.
• [36] LIAW M Y,HSU C H,LEONG C P,et al.Respiratory muscle training in stroke patients with respiratory muscle weakness,dysphagia,and dysarthria-a prospective randomized trial[J]. Medicine,2020,99(1):22-27. DOI:10.1097/MD.0000000000019337.